CAS: 36703-88-5; 4-Acetamidobenzoic Acid,9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)-3H-Purin-6(9H)-One,1-(Dimethylamino)Propan-2-Ol (3:1:3)

专利信息

专利号:US-2003180254-A1
优先权日:1995-05-26
标题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:GOVT OF THE USA AS REPRESENTED
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

专利号:US-10065924-B2
优先权日:2014-07-22
标 题 :Preparation and biological evaluation of viridicatumtoxin analogs
发明人：NICOLAOU KYRIACOS C; HALE CHRISTOPHER R H; NILEWSKI CHRISTIAN; IOANNIDOU HERAKLIDIA; EL MARROUNI ABDELLATIF
权利人:UNIV RICE WILLIAM M
摘要:In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.

专利号:ES-2794012-T3
优先权日:2008-10-27
标题 :Intermediaries for the synthesis of mTOR kinase inhibitors

专利号:US-2017298175-A1
优先权日:2016-04-14
标题:Highly elastic and moldable polyester biomaterial for cardiac tissue engineering applications
发明人：RADISIC MILICA; Huyer Locke Davenport; MONTGOMERY MILES
权利人:RADISIC MILICA; Huyer Locke Davenport; MONTGOMERY MILES
摘要:The present invention provides a new polyester biomaterial through a simple one-step polycondensation synthesis. 124 polymer exhibited highly elastic properties under aqueous conditions that were tunable according to the UV light exposure, monomer composition, and porosity of the cured elastomer. Its elastomeric properties fell within the range of adult heart myocardium, but they could also be optimized for higher elasticity for weaker immature constructs. The polymer showed relatively stable degradation characteristics, both hydrolytically and in a cellular environment, suggesting maintenance of material properties as a scaffold support for potential tissue implants. When assessed for cell interaction, this polymer supported rat cardiac cell attachment in vitro as well as decreased fibrous capsule formation in vivo when compared to poly(L-lactic acid) control. This suggests the potential applicability of this material as an elastomer for cardiac tissue engineered constructs. Furthermore, the highly elastic polyester could be molded and photocrosslinked into a complex mesh structure with feature size on the order of tens of micrometers, demonstrating utility in cardiac tissue engineering constructs.

专利号:US-7199128-B2
优先权日:2005-02-02
标题 :8-N-substituted-2H-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents
发明人：BRADBURY BARTON J; WILES JASON ALLAN; DESHPANDE MILIND; WANG QIUPING; HASHIMOTO AKIHIRO; LUCIEN EDLAINE
权利人:ACHILLION PHARMACEUTICALS INC
摘要:The invention provides compounds and salts of Formula I and Formula II: n nwhich possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A 1 , A 8 , R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 are defined herein.n n Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of compounds of Formula I and/or Formula II and one or more other active agents. The invention also provides methods for treating microbial and protozoal infections in animals.

专利号:US-5696079-A
优先权日:1993-05-19
标 题:Immunologic enhancement with intermittent interleukin-2 therapy
发明人：LANE H CLIFFORD; KOVACS JOSEPH A; FAUCI ANTHONY S
权利人:US HEALTH
摘要:A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.